RESUMEN
BACKGROUND: Immunotherapy with PD-1 or PD-L1 blockade fails to induce a response in about 80% of patients with unselected non-small cell lung cancer (NSCLC), and many of those who do initially respond then develop resistance to treatment. Agonists that target the shared interleukin-2 (IL-2) and IL-15Rßγ pathway have induced complete and durable responses in some cancers, but no studies have been done to assess the safety or efficacy of these agonists in combination with anti-PD-1 immunotherapy. We aimed to define the safety, tolerability, and activity of this drug combination in patients with NSCLC. METHODS: In this non-randomised, open-label, phase 1b trial, we enrolled patients (aged ≥18 years) with previously treated histologically or cytologically confirmed stage IIIB or IV NSCLC from three academic hospitals in the USA. Key eligibility criteria included measurable disease, eligibility to receive anti-PD-1 immunotherapy, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients received the anti-PD-1 monoclonal antibody nivolumab intravenously at 3 mg/kg (then 240 mg when US Food and Drug Administration [FDA]-approved dosing changed) every 14 days (either as new treatment or continued treatment at the time of disease progression) and the IL-15 superagonist ALT-803 subcutaneously once per week on weeks 1-5 of four 6-week cycles for 6 months. ALT-803 was administered at one of four escalating dose concentrations: 6, 10, 15, or 20 µg/kg. The primary endpoint was to define safety and tolerability and to establish a recommended phase 2 dose of ALT-803 in combination with nivolumab. Analyses were per-protocol and included any patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, number NCT02523469; phase 2 enrolment of patients is ongoing. FINDINGS: Between Jan 18, 2016, and June 28, 2017, 23 patients were enrolled and 21 were treated at four dose levels of ALT-803 in combination with nivolumab. Two patients did not receive treatment because of the development of inter-current illness during enrolment, one patient due to leucopenia and one patient due to pulmonary dysfunction. No dose-limiting toxicities were recorded and the maximum tolerated dose was not reached. The most common adverse events were injection-site reactions (in 19 [90%] of 21 patients) and flu-like symptoms (15 [71%]). The most common grade 3 adverse events, occurring in two patients each, were lymphocytopenia and fatigue. A grade 3 myocardial infarction occurred in one patient. No grade 4 or 5 adverse events were recorded. The recommended phase 2 dose of ALT-803 is 20 µg/kg given once per week subcutaneously in combination with 240 mg intravenous nivolumab every 2 weeks. INTERPRETATION: ALT-803 in combination with nivolumab can be safely administered in an outpatient setting. The promising clinical activity observed with the addition of ALT-803 to the regimen of patients with PD-1 monoclonal antibody relapsed and refractory disease shows evidence of anti-tumour activity for a new class of agents in NSCLC. FUNDING: Altor BioScience (a NantWorks company), National Institutes of Health, and Medical University of South Carolina Hollings Cancer Center.
Asunto(s)
Antineoplásicos Inmunológicos/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Neoplasias Pulmonares/tratamiento farmacológico , Nivolumab/administración & dosificación , Proteínas/administración & dosificación , Anciano , Antineoplásicos Inmunológicos/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Carcinoma de Pulmón de Células no Pequeñas/secundario , Femenino , Humanos , Neoplasias Pulmonares/patología , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Nivolumab/efectos adversos , Proteínas/efectos adversos , Proteínas Recombinantes de Fusión , Factores de Tiempo , Resultado del Tratamiento , Estados UnidosRESUMEN
Developing T cells face a series of cell fate choices in the thymus and in the periphery. The role of the individual T cell receptor (TCR) in determining decisions of cell fate remains unresolved. The stochastic/selection model postulates that the initial fate of the cell is independent of TCR specificity, with survival dependent on additional TCR/coreceptor "rescue" signals. The "instructive" model holds that cell fate is initiated by the interaction of the TCR with a cognate peptide-MHC complex. T cells are then segregated on the basis of TCR specificity with the aid of critical coreceptors and signal modulators [Chan S, Correia-Neves M, Benoist C, Mathis (1998) Immunol Rev 165: 195-207]. The former would predict a random representation of individual TCR across divergent T cell lineages whereas the latter would predict minimal overlap between divergent T cell subsets. To address this issue, we have used high-throughput sequencing to evaluate the TCR distribution among key T cell developmental and effector subsets from a single donor. We found numerous examples of individual subsets sharing identical TCR sequence, supporting a model of a stochastic process of cell fate determination coupled with dynamic patterns of clonal expansion of T cells bearing the same TCR sequence among both CD4(+) and CD8+ populations.
Asunto(s)
Receptores de Antígenos de Linfocitos T/inmunología , Subgrupos de Linfocitos T/inmunología , Secuencia de Aminoácidos , Diferenciación Celular , Linaje de la Célula , Humanos , Receptores de Antígenos de Linfocitos T/química , Subgrupos de Linfocitos T/química , Subgrupos de Linfocitos T/citologíaRESUMEN
Many health professionals use large datasets to answer behavioral, translational, or clinical questions. Understanding the impact of missing data in large databases, such as disease registries, can avoid erroneous interpretations of these data. Using the California Cancer Registry, the authors selected seven common cancers, seven sociodemographic and clinical variables, and the top three reporting sources, as examples of the type of data that would be deemed critical to most studies. The gender variable had no missing data, followed by age (<0.1 % missing), ethnicity (1.7 %), stage (9.8 %), differentiation (39.1 %), and birthplace (41.1 %). Reports from hospitals and clinics had the lowest percentages of missing data. Users of large datasets should anticipate the limitations of missing data to prevent methodological flaws and misinterpretations of research findings. Knowledge of what and how much data may be missing in large datasets can help prevent errors in research conclusions, while better guiding treatment modalities and public health policies and programs.
Asunto(s)
Interpretación Estadística de Datos , Etnicidad/estadística & datos numéricos , Neoplasias/epidemiología , Sistema de Registros , Factores de Edad , Recolección de Datos , Humanos , Neoplasias/diagnósticoRESUMEN
From May through October 2009, a total of 10,624 clinical samples from 23 US states were screened for multiple respiratory pathogen gene targets. Of 3,110 (29.3%) samples positive for pandemic (H1N1) 2009 virus, 28% contained ≥ 1 other pathogen, most commonly Staphylococcus aureus (14.7%), Streptococcus pneumoniae (10.2%), and Haemophilus influenzae (3.5%).
Asunto(s)
Infecciones Bacterianas/epidemiología , Brotes de Enfermedades , Subtipo H1N1 del Virus de la Influenza A/aislamiento & purificación , Gripe Humana/epidemiología , Infecciones del Sistema Respiratorio/epidemiología , Streptococcus pneumoniae/aislamiento & purificación , Adolescente , Factores de Edad , Infecciones Bacterianas/microbiología , Niño , Preescolar , Haemophilus influenzae/genética , Haemophilus influenzae/aislamiento & purificación , Humanos , Subtipo H1N1 del Virus de la Influenza A/genética , Nasofaringe/microbiología , Reacción en Cadena de la Polimerasa , Juego de Reactivos para Diagnóstico , Infecciones del Sistema Respiratorio/microbiología , Staphylococcus aureus/genética , Staphylococcus aureus/aislamiento & purificación , Streptococcus pneumoniae/genética , Estados Unidos/epidemiologíaRESUMEN
Glioblastoma is the most common primary malignant brain tumor in adults and is associated with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a randomized, multi-institution clinical trial to evaluate immune responses and survival following neoadjuvant and/or adjuvant therapy with pembrolizumab in 35 patients with recurrent, surgically resectable glioblastoma. Patients who were randomized to receive neoadjuvant pembrolizumab, with continued adjuvant therapy following surgery, had significantly extended overall survival compared to patients that were randomized to receive adjuvant, post-surgical programmed cell death protein 1 (PD-1) blockade alone. Neoadjuvant PD-1 blockade was associated with upregulation of T cell- and interferon-γ-related gene expression, but downregulation of cell-cycle-related gene expression within the tumor, which was not seen in patients that received adjuvant therapy alone. Focal induction of programmed death-ligand 1 in the tumor microenvironment, enhanced clonal expansion of T cells, decreased PD-1 expression on peripheral blood T cells and a decreasing monocytic population was observed more frequently in the neoadjuvant group than in patients treated only in the adjuvant setting. These findings suggest that the neoadjuvant administration of PD-1 blockade enhances both the local and systemic antitumor immune response and may represent a more efficacious approach to the treatment of this uniformly lethal brain tumor.
Asunto(s)
Anticuerpos Monoclonales Humanizados/uso terapéutico , Antineoplásicos Inmunológicos/uso terapéutico , Neoplasias Encefálicas/tratamiento farmacológico , Glioblastoma/tratamiento farmacológico , Recurrencia Local de Neoplasia/tratamiento farmacológico , Receptor de Muerte Celular Programada 1/antagonistas & inhibidores , Microambiente Tumoral/inmunología , Adulto , Anciano , Neoplasias Encefálicas/inmunología , Quimioterapia Adyuvante , Femenino , Glioblastoma/inmunología , Humanos , Masculino , Persona de Mediana Edad , Terapia Neoadyuvante , Recurrencia Local de Neoplasia/inmunología , Procedimientos Neuroquirúrgicos , Receptor de Muerte Celular Programada 1/inmunología , Tasa de Supervivencia , Linfocitos T/inmunologíaRESUMEN
Purpose: Radiotherapy is a highly effective anticancer treatment forming part of the standard of care for the majority of patients, but local and distal disease recurrence remains a major cause of mortality. Radiotherapy is known to enhance tumor immunogenicity; however, the contribution and mechanisms of radiotherapy-induced immune responses are unknown.Experimental Design: The impact of low-dose fractionated radiotherapy (5 × 2 Gy) alone and in combination with αPD-1 mAb on the tumor microenvironment was evaluated by flow cytometry and next-generation sequencing of the T-cell receptor (TCR) repertoire. A dual-tumor model was used, with fractionated radiotherapy delivered to a single tumor site to enable evaluation of the local and systemic response to treatment and ability to induce abscopal responses outside the radiation field.Results: We show that fractionated radiotherapy leads to T-cell infiltration at the irradiated site; however, the TCR landscape remains dominated by polyclonal expansion of preexisting T-cell clones. Adaptive resistance via the PD-1/PD-L1 pathway restricts the generation of systemic anticancer immunity following radiotherapy, which can be overcome through combination with αPD-1 mAb leading to improved local and distal tumor control. Moreover, we show that effective clearance of tumor following combination therapy is dependent on both T cells resident in the tumor at the time of radiotherapy and infiltrating T cells.Conclusions: These data provide evidence that radiotherapy can enhance T-cell trafficking to locally treated tumor sites and augment preexisting anticancer T-cell responses with the capacity to mediate regression of out-of-field tumor lesions when delivered in combination with αPD-1 mAb therapy. Clin Cancer Res; 23(18); 5514-26. ©2017 AACR.
Asunto(s)
Antineoplásicos Hormonales/farmacología , Linfocitos Infiltrantes de Tumor/efectos de los fármacos , Linfocitos Infiltrantes de Tumor/inmunología , Linfocitos Infiltrantes de Tumor/efectos de la radiación , Neoplasias/inmunología , Neoplasias/patología , Receptor de Muerte Celular Programada 1/antagonistas & inhibidores , Subgrupos de Linfocitos T/efectos de los fármacos , Subgrupos de Linfocitos T/inmunología , Subgrupos de Linfocitos T/efectos de la radiación , Animales , Línea Celular Tumoral , Terapia Combinada , Citocinas/metabolismo , Modelos Animales de Enfermedad , Humanos , Linfocitos Infiltrantes de Tumor/metabolismo , Ratones , Neoplasias/metabolismo , Neoplasias/terapia , Receptor de Muerte Celular Programada 1/metabolismo , Radioterapia , Receptores de Antígenos de Linfocitos T alfa-beta/metabolismo , Tasa de Supervivencia , Subgrupos de Linfocitos T/metabolismo , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
The present investigation examined variations in cytokine and Toll-like receptor expression by T-lymphocytes in HIV infection. 50 HIV cases and 10 normal controls were evaluated for TLR3, TLR4, TLR8, TLR9, IL-2, IL-4, IL-6, IL-10, IL-12, TNF-alpha, and IFN-gamma expression and staining intensities. TLR3 was expressed in 37 HIV (74%) cases, and TLR4 was brightly expressed in all (100%) HIV cases. However, TLR3 and TLR4 remained negative in all normal controls. Results reveal that TLR4 up-regulation is not limited to gram-negative bacterial infection. No statistical difference was detected when TLR8 and TLR9 expression were compared between the two test populations. A statistically significant difference was detected when IL-2, IL-4, IL-6, IL-10, IL-12, and IFN-gamma expression were analyzed in HIV cases and normal controls. When cytokine expression was compared with stage of disease, results indicated that a Th(1) to Th(2) cytokine switch did not occur. Only TNF-alpha expression decreased as infection progressed from the chronic phase into AIDS. When TLR expression was compared to cytokine expression, no statistical differences were detected. These data point to the need for a more in-depth study to determine whether or not the up-regulation of Toll-like receptor expression increases cytokine expression via the NFkappaB pathway.
Asunto(s)
Citocinas/inmunología , VIH-1/inmunología , Isoformas de Proteínas/inmunología , Receptores Toll-Like/inmunología , Femenino , Infecciones por VIH/inmunología , Humanos , Subgrupos Linfocitarios , Masculino , Isoformas de Proteínas/genética , Linfocitos T/inmunología , Receptores Toll-Like/genéticaRESUMEN
Zeta-chain (TCR)-associated protein kinase 70 kDa (Zap-70) and CD38 expression may be of prognostic significance in chronic lymphocytic leukemia (CLL). Previous studies indicate that Zap-70 and CD38 are usually positive in cases of CLL with unmutated immunoglobulin variable region genes (IgVH) and may be used to predict IgVH mutation status and prognosis. Usually cases of CLL positive for Zap-70 or CD38 indicate a worse prognosis. In the present investigation, 47 cases of CLL were evaluated for CD38 expression, and 17 cases were evaluated for both Zap-70 and CD38 expression. Of the 47 cases, 19 (40.4%) positively expressed CD38. Of the 17 cases evaluated for Zap-70, 11 (64.7%) were positive for Zap-70, while only 6 (35.3%) were positive for CD38 expression; the remaining cases were negative for CD38. The results of this study show that Zap-70 expression may be a better indicator of the mutational status of IgVH and prognosis of CLL than CD38 expression. In addition, CD38 negativity does not necessarily indicate that IgVH mutation has occurred. These data point to the need for a more extensive study to evaluate the significance of Zap-70 and CD38 expression as indicators of IgVH mutation status and prognosis of CLL patients.
Asunto(s)
ADP-Ribosil Ciclasa 1/metabolismo , Región Variable de Inmunoglobulina/genética , Leucemia Linfocítica Crónica de Células B , Glicoproteínas de Membrana/metabolismo , Proteína Tirosina Quinasa ZAP-70/metabolismo , ADP-Ribosil Ciclasa 1/genética , Predisposición Genética a la Enfermedad , Humanos , Leucemia Linfocítica Crónica de Células B/diagnóstico , Leucemia Linfocítica Crónica de Células B/genética , Leucemia Linfocítica Crónica de Células B/inmunología , Glicoproteínas de Membrana/genética , Mutación , Pronóstico , Proteína Tirosina Quinasa ZAP-70/genéticaRESUMEN
According to WHO, several T-cell immunophenotypic markers may be aberrantly expressed in acute myeloid leukemia (AML). TdT may be expressed in greater than one-third of cases, and CD2 and CD7 may be expressed frequently at low intensity; however, the T-cell lineage specific antigen CD3 is usually absent. In this investigation, 30 cases of AML were evaluated for CD2, CD3, CD5, CD7, CD8 and TdT expression, and mean fluorescence intensities (MFI). Of the 3 (10%) cases positive for CD3 and CD8, 1 was bright (MFI>501), and 2 cases were moderate. TdT was moderately expressed in 4 (13.3%) cases with MFI values between 301 and 500. CD2 and CD5 were positive in 5 (16.7%) cases. While CD2 was moderate in all 5 cases, CD5 was bright in 3, moderate in 1 and dim in 1. Of the 15 (50%) cases positive for CD7, 9 were bright, 5 were moderate, and 1 was dim with a MFI value between 201 and 300. These data indicate that CD2 and CD7 may be frequently expressed at greater intensities than WHO specified. These results point to the need for a more extensive study to evaluate the potential prognostic significance of aberrant T-cell marker expression in AML.
Asunto(s)
Antígenos CD/metabolismo , Biomarcadores/metabolismo , Leucemia Mieloide Aguda/inmunología , Linfocitos T/metabolismo , Humanos , InmunofenotipificaciónRESUMEN
Acute myelogenous leukemia (AML) is divided into 8 FAB subgroups based on differentiation and maturation properties of the neoplastic cells. Acute promyelocytic leukemia (APL), or M3 AML, is associated with disseminated intravascular coagulation (DIC). Flow cytometric immunophenotyping differentiates among the AML subtypes. Key markers in this classification include the myeloid antigens CD13 and CD33 and the hematopoietic precursor markers CD34 and HLA-DR. The present study analyzes and compares differences in the expression of these markers in 27 M0-M2 cases and 8 M3 cases. The M0-M2 cases generally expressed all four antigens. CD13 and CD33 were positively expressed in 23 (85.2%) and 21 (77.8%) of the 27 cases, respectively. CD34 and HLA-DR were present in 25 (92.6%) and 26 (96.3%) of the 27 cases, respectively. Analysis of the M3 cases revealed a different immunophenotype as CD13 and CD33 were each positive in all 8 (100%) M3 AML cases while CD34 and HLA-DR were negative in 6 (75%) and 8 (100%) of the 8 M3 cases, respectively. In contrast to expression of the early markers CD34 and HLA-DR in the M0-M2 group, these were negative in the M3 cases which were characterized by heterogeneous CD13 and generally homogeneous and bright CD33 expression.
Asunto(s)
Antígenos de Neoplasias/análisis , Leucemia Mieloide Aguda/patología , Antígenos CD/análisis , Antígenos CD34/análisis , Antígenos HLA-DR/análisis , Humanos , Leucemia Mieloide Aguda/clasificación , Leucemia Mieloide Aguda/inmunología , Estadificación de NeoplasiasRESUMEN
Flow cytometric analysis of cluster of differentiation (CD) markers of myeloid cells has been used in conjunction with cell morphology to diagnose chronic myelogenous leukemia (CML). In the present study, 16 cases of CML were studied for levels of expression of myeloid markers CD15, CD13, CD33, and CALLA, i.e., CD10 which is also expressed on mature granulocytes. In 11 (68.8%) of 16 cases, a differentiated granulocyte population was detected that showed decreased expression of both CD10 and CD13. CD10 was found to be negative in 1 (6.3%) case and showed decreased expression in 10 (62.5%) of the cases. CD13 showed decreased expression in 11 (68.8%) of the 16 cases. Of the 15 cases analyzed for CD15, 2 (13.3%) were negative and 6 (40%) showed decreased expression. Of the 11 cases which showed simultaneous diminished expression of CD10 and CD13, 8 (72.7%) also showed decreased expression of CD15. Of the antigens studied, CD33 was the only one to be consistently expressed at normal levels, i.e., 13 (81.3%) cases demonstrated normal expression. Therefore, these results point to frequently decreased expression levels of CD10, CD13, and CD15 and rarely decreased expression levels of CD33 in association with CML.
Asunto(s)
Antígenos CD/genética , Antígenos CD13/genética , Granulocitos/patología , Leucemia Mielógena Crónica BCR-ABL Positiva/genética , Leucemia Mielógena Crónica BCR-ABL Positiva/inmunología , Antígeno Lewis X/genética , Neprilisina/genética , Antígenos de Diferenciación Mielomonocítica/genética , Diferenciación Celular , Citometría de Flujo , Humanos , Leucemia Mielógena Crónica BCR-ABL Positiva/patología , Lectina 3 Similar a Ig de Unión al Ácido SiálicoRESUMEN
Flow cytometric analysis of cluster of differentiation (CD) markers in abnormal lymphocyte populations is crucial in the diagnosis of precursor T cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL). The World Health Organization (WHO) suggested immunophenotype for pre-T ALL/LBL typically includes the expression of TdT, cCD3, and CD7, while CD2, CD3, CD4, CD5, CD8, and CD10 are variably expressed. The myeloid antigens CD13 and CD33 are usually positive, whereas CD117 and cCD79a are infrequently expressed. Furthermore, there is frequent dual expression of CD4 and CD8. In the present investigation, 19 cases of pre-TALL/LBL were analyzed for selected CD marker expression. Fifteen of 19 cases studied were evaluated for TdT, cCD3, and cCD79a expression. Eleven (73.3%) positively expressed TdT, 15 (100%) positively expressed cCD3, and 9 (60%) positively expressed cCD79a. Of the 17 cases analyzed for CD7, CD5, and CD10 expression, CD7 and CD5 were positive in all 17 (100%) cases, whereas CD10 was positive in 8 (47.1%) cases. Of the 18 cases evaluated for CD2, CD3, CD4, CD8, and dual expression of CD4 and CD8, CD2 was expressed in 14 (77.8%), while CD3 was expressed in 7 (38.9%) cases. CD4 was positive in 11 (61.1%), and CD8 was expressed in 9 (50%). Dual expression of CD4 and CD8 occurred in only 4 (22.2%) of the cases. Of the 16 analyzed for CD13, CD33, and CD117, only 1 case (6.3%) expressed CD13, while 2 (12.5%) cases expressed CD33 and CD117. Thus, these data point to the need for a more extensive study to reevaluate the current WHO defined immunophenotype used in the diagnosis of pre-TALL/LBL.
Asunto(s)
Antígenos CD/metabolismo , Inmunofenotipificación , Leucemia-Linfoma de Células T del Adulto/metabolismo , Leucemia-Linfoma Linfoblástico de Células Precursoras/metabolismo , Citometría de Flujo , Humanos , Leucemia-Linfoma de Células T del Adulto/inmunología , Leucemia-Linfoma de Células T del Adulto/patología , Leucemia-Linfoma Linfoblástico de Células Precursoras/inmunología , Leucemia-Linfoma Linfoblástico de Células Precursoras/patologíaRESUMEN
The WHO immunophenotype for plasma cell myeloma is deletion of CD19 and CD20, usual expression of CD38, CD138, and CD56, and occasional expression of CD10. Of the 39 cases of plasma cell dyscrasia in our study, the mean fluorescence intensities (MFI) of CD38, CD138, CD56, and CD19 were quantified in 30 cases. CD19 was absent in 38 of the cases (97.4%), whereas CD138 and CD38 were expressed in all 39 cases (100%). Most cases expressed CD38 and CD138 brightly with MFI values greater than 501, whereas all other marker expression was moderate with MFI greater than 301. Whereas CD38/CD56 dual expression was observed in 25 cases (64.1%), 14 failed to express CD56 (35.9%). CD56 expression was bright in 16 cases (53.3%), moderate in 2 cases (6.7%), and negative in the remaining 12 cases (40%) with MFI values of 200 or less. CD117 expression was positive in 9 of 24 cases (37.5%). In 32 of 39 cases, 27 were negative for CD20 (84.4%) and 28 were negative for CD10 (87.5%). Our results point to the value of quantitative fluorescence intensity in the flow cytometric evaluation of CD molecular expression or deletion in the diagnosis of hematopathologic disorders, such as plasma cell dyscrasia.